GMAB GENMAB A/S IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1434265
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q2*2025-06-30 · USD | 2024Q2*2024-06-30 · DKK | 2023Q2*2023-06-30 · DKK | 2022Q2*2022-06-30 · DKK | 2021Q2*2021-06-30 · DKK | 2020Q2*2020-06-30 · DKK | 2019Q2*2019-06-30 · DKK | 2018Q2*2018-06-30 · DKK |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $925.00M | 5.40B | 4.17B | 3.16B | 1.97B | 5.45B | 774.00M | 509.68M |
| Cost of revenue | $57.00M | 190.00M | 21.00M | — | — | — | — | — |
| Gross profit | $868.00M | 5.21B | 4.15B | — | — | — | — | — |
| R&D expense | $364.00M | 2.50B | 1.85B | 1.28B | 921.00M | 775.00M | 564.00M | 318.89M |
| SG&A expense | $144.00M | 894.00M | 827.00M | 633.00M | 264.00M | 179.00M | 73.00M | 55.74M |
| Operating income | $360.00M | 1.64B | 1.47B | 1.25B | 787.00M | 4.50B | 137.00M | 135.04M |
| Interest expense | $91.00M | 399.00M | 120.00M | 200.00M | 430.00M | 211.00M | 60.00M | — |
| Pretax income | $423.00M | 2.13B | 1.69B | 2.49B | 422.00M | 4.33B | 111.00M | 335.31M |
| Income tax | $87.00M | 719.00M | 359.00M | 598.00M | 116.00M | 950.00M | 26.00M | 74.79M |
| Net income | $336.00M | 1.41B | 1.33B | 1.89B | 306.00M | 3.38B | 85.00M | 260.53M |
| EPS (basic) | 5.44 | 21.85 | 20.46 | 28.87 | 4.68 | 51.88 | 1.38 | 4.26 |
| EPS (diluted) | 5.42 | 21.70 | 20.28 | 28.66 | 4.64 | 51.35 | 1.35 | 4.21 |
| Balance sheet | ||||||||
| Cash & equivalents | $1.30B | 4.33B | 10.87B | 9.82B | 9.48B | 6.61B | 583.00M | 1.09B |
| Receivables | $998.00M | 6.17B | 4.69B | 3.88B | 2.43B | 6.36B | 859.91M | — |
| Inventory | $13.00M | 36.00M | 51.00M | — | — | — | — | — |
| Current assets | $3.91B | 21.94B | 29.75B | 25.49B | 20.30B | 19.14B | 7.81B | — |
| PP&E, netmay include right-of-use assets (IFRS) | $152.00M | 952.00M | 908.00M | 684.00M | 535.00M | 414.00M | 175.95M | — |
| Goodwill | $355.00M | 2.52B | — | — | — | — | — | — |
| Intangibles | $1.75B | 12.01B | 129.00M | 216.00M | 297.00M | 413.00M | 421.43M | — |
| Total assets | $6.46B | 38.62B | 31.98B | 27.48B | 22.48B | 20.68B | 8.98B | — |
| Current liabilities | $629.00M | 4.36B | 1.99B | 1.94B | 1.35B | 2.01B | 524.56M | — |
| Total liabilities | $1.16B | 7.65B | 3.22B | 2.99B | 2.23B | 2.81B | 690.80M | — |
| Shareholders' equity | $5.30B | 30.97B | 28.56B | 24.48B | 20.25B | 17.87B | 8.29B | 6.86B |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | — | — | — | — | — |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.